Microbix Biosystems Inc.’s funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (CDMO) for production of the active ingredient of Kinlytic urokinase, a biologic drug for dissolving blood clots.   Sequel is a U.S. based specialty pharma company with expertise in developing and commercializing niche drugs. It has committed to provide all funding needed to ...